...
首页> 外文期刊>Antiviral chemistry & chemotherapy >Characterization of human immunodeficiency virus type 1 strains resistant to the non-nucleoside reverse transcriptase inhibitor RD4-2217.
【24h】

Characterization of human immunodeficiency virus type 1 strains resistant to the non-nucleoside reverse transcriptase inhibitor RD4-2217.

机译:对非核苷类逆转录酶抑制剂RD4-2217耐药的1型人类免疫缺陷病毒株的特征。

获取原文
获取原文并翻译 | 示例
           

摘要

The non-nucleoside reverse transcriptase (RT) inhibitor RD4-2217 is a thiadiazole derivative that has proved to be a highly potent and selective inhibitor of human immunodeficiency virus type 1 (HIV-1) replication in vitro. In this study we examined genotypic and phenotypic characteristics of RD4-2217-resistant mutants that have been obtained by serial passage of HIV-1 in MT-4 cells in the presence of increasing concentrations (0.05, 0.25, 1 and 10 microM) of the compound. The strains obtained, III(B/2217RE/0.05) and III(B/2217RE/0.25,) were two- and 15-fold resistant to RD4-2217, respectively, whereas III(B/2217RE/1) and III(B/2217RE/10) displayed 161- and >238-fold resistance, respectively. Both III(B/2217RE/1) and III(B/2217RE/10) had two amino acid substitutions, V1891 and T2401, in the RT. Furthermore, RD4-2217 did not inhibit the replication of an HIV-1 molecular clone, which had the same mutation, at concentrations up to 10 microM, indicating that the V1891 plus T2401 mutation confers high-level resistance to RD4-2217. Interestingly, the replicability of III(B2217RE/1) and III(B/2217RE/10) appeared to be lower than that of wildtype III(B) in MT-4 cells, suggesting that the V1891 plus T2401 mutation may impair the enzymatic activity of HIV-1 RT.
机译:非核苷逆转录酶(RT)抑制剂RD4-2217是噻二唑衍生物,已被证明是1型人类免疫缺陷病毒(HIV-1)体外复制的高效和选择性抑制剂。在这项研究中,我们研究了RD4-2217抗性突变体的基因型和表型特征,这些突变体是通过在浓度不断增加的(0.05、0.25、1和10 microM)的MT-4细胞中将HIV-1连续传代而获得的。复合。获得的菌株III(B / 2217RE / 0.05)和III(B / 2217RE / 0.25,)分别对RD4-2217具有2倍和15倍的抗性,而III(B / 2217RE / 1)和III(B / 2217RE / 10)分别显示161倍和> 238倍的电阻。 III(B / 2217RE / 1)和III(B / 2217RE / 10)在RT中均具有两个氨基酸取代,即V1891和T2401。此外,RD4-2217在最高10 microM的浓度下也没有抑制具有相同突变的HIV-1分子克隆的复制,表明V1891加T2401突变赋予了对RD4-2217的高水平抗性。有趣的是,III(B2217RE / 1)和III(B / 2217RE / 10)在MT-4细胞中的复制性似乎低于野生型III(B),这表明V1891加T2401突变可能会损害酶的活性。 HIV-1 RT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号